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ABSTRACT
Background Patients with rheumatoid arthritis (RA)
are at increased risk of developing comorbid
conditions.
Objectives To evaluate the prevalence of comorbidities
and compare their management in RA patients from
different countries worldwide.
Methods Study design: international, cross-sectional.
Patients: consecutive RA patients. Data collected:
demographics, disease characteristics (activity, severity,
treatment), comorbidities (cardiovascular, infections,
cancer, gastrointestinal, pulmonary, osteoporosis and
psychiatric disorders).
Results Of 4586 patients recruited in 17 participating
countries, 3920 were analysed (age, 56±13 years;
disease duration, 10±9 years (mean±SD); female
gender, 82%; DAS28 (Disease Activity Score using
28 joints)–erythrocyte sedimentation rate, 3.7±1.6
(mean±SD); Health Assessment Questionnaire, 1.0±0.7
(mean±SD); past or current methotrexate use, 89%; past
or current use of biological agents, 39%. The most
frequently associated diseases (past or current) were:
depression, 15%; asthma, 6.6%; cardiovascular events
(myocardial infarction, stroke), 6%; solid malignancies
(excluding basal cell carcinoma), 4.5%; chronic
obstructive pulmonary disease, 3.5%. High intercountry
variability was observed for both the prevalence of
comorbidities and the proportion of subjects complying
with recommendations for preventing and managing
comorbidities. The systematic evaluation of comorbidities
in this study detected abnormalities in vital signs, such
as elevated blood pressure in 11.2%, and identiﬁed
conditions that manifest as laboratory test abnormalities,
such as hyperglycaemia in 3.3% and hyperlipidaemia in
8.3%.
Conclusions Among RA patients, there is a high
prevalence of comorbidities and their risk factors. In this
multinational sample, variability among countries was
wide, not only in prevalence but also in compliance with
recommendations for preventing and managing these
comorbidities. Systematic measurement of vital signs and
laboratory testing detects otherwise unrecognised
comorbid conditions.
INTRODUCTION
The long-term prognosis of rheumatoid arthritis
(RA) has improved dramatically following the intro-
duction of highly effective medications, such as
methotrexate leﬂunomide and biological agents,1 2
and as the result of close monitoring and regular
adjustment of treatment to the targets of low disease
activity or remission.3 However, comorbidities may
shorten the life span of patients with RA.4–6 This
higher death rate appears to be the consequence of
an increased prevalence of cardiovascular disease, a
greater incidence of infections, and the development
of certain malignancies in patients with RA.7–11
Also, osteoporotic fractures are more commonly
observed in patients with RA and signiﬁcantly affect
the prognosis for functional decline.12 13 In add-
ition, RA patients with more comorbidities experi-
ence greater functional impairment.14
Some of these comorbidities are observed more
often among RA patients because of the medica-
tions with which they are treated, especially gluco-
corticoids,10 and because of traditional risk factors,
such as tobacco smoking.15 However, chronically
active inﬂammation also predisposes to the devel-
opment of these comorbidities.16
Unfortunately, comorbidities are not well
managed in RA patients.17–20 To address this dispar-
ity, the European League Against Rheumatism
(EULAR) proposed speciﬁc recommendations for
detecting and managing speciﬁc comorbidities and
preventing their development when possible. These
include recommendations that all patients with RA
should be vaccinated against inﬂuenza every year
and against pneumococci every 5 years21 and should
be evaluated for cardiovascular risk annually.
Because chronically active inﬂammation contributes
to the development of cardiovascular disease, these
recommendations suggest that the cardiovascular
risk score be multiplied by a factor of 1.5 when two
of the following three criteria are met: (1) disease
duration longer than 10 years; (2) presence of
circulating rheumatoid factor or anti-citrullinated
protein antibodies; (3) presence of extra-articular
manifestations.22
Open Access
Scan to access more
free content
62 Dougados M, et al. Ann Rheum Dis 2014;73:62–68. doi:10.1136/annrheumdis-2013-204223
Clinical and epidemiological research
 group.bmj.com on January 9, 2014 - Published by ard.bmj.comDownloaded from 
The COMORA (COMOrbidities in Rheumatoid Arthritis)
Study had two major objectives. The ﬁrst was to evaluate vari-
ability in the prevalence of comorbidities and their risk factors
between participating countries. The second was to assess
whether there is a disparity between existing national recom-
mendations and the actions implemented in daily clinical prac-
tice to detect and prevent the development of these
comorbidities.
PATIENTS AND METHODS
Study design
This was a cross-sectional, observational, multicentre, inter-
national study.
Patient recruitment
The scientiﬁc committee chose national principal investigators
for this study. Their task was to select rheumatologists who
would be representative of their country and to conduct the
study in accordance with good clinical practice. The protocol
was reviewed and approved by all local institutional review
boards or ethics committees. Consecutive patients visiting the
participating rheumatologists were invited to enrol in the study
if they were at least 18 years of age, fulﬁlled the 1987 American
College of Rheumatology classiﬁcation criteria for RA,23 and
were able to understand and complete the questionnaires that
were administered. Written informed consent was obtained
from all subjects before enrolment.
Sample size
The sample size calculation was based on the precision (width)
of the 95% CI of the proportions of expected events (eg, preva-
lence of each comorbidity). For example, it was calculated that a
sample of 4000 patients would allow the 35% prevalence of a
given comorbidity, X, to be estimated with a precision of 1.5%
(95% CI 33.5% to 36.5%), or the 1% prevalence of another
comorbidity, Y, to be estimated with a precision of 0.3% (95%
CI 0.7% to 1.3%).
Investigators in each participating country were expected to
enrol at least 200 patients.
Data collected
A case report form speciﬁcally created for this study was used to
collect four categories of data.
1. Characteristics of demographics and the disease. Patients’
demographic characteristics included: age, gender, body mass
index, smoking status, alcohol intake, marital status, socio-
economic status and highest level of education completed.
Disease activity was assessed using the DAS28 (Disease Activity
Score using 28 joints)–erythrocyte sedimentation rate (ESR)24
and the C-reactive protein level. Disease severity was evaluated
from the history of joint surgery to address structural damage
caused by RA (eg, total joint arthroplasty, arthrodesis, metacar-
pophalangeal or metatarsophalangeal joint resections). Past
and current medications used to treat RA were also recorded,
including non-steroidal anti-inﬂammatory drugs, corticoster-
oids and conventional and biological disease-modifying anti-
rheumatic drugs (DMARDs).
2. History or current evidence of comorbidities. Ischaemic car-
diovascular disease (myocardial infarction, stroke), cancers
(colon, skin, lung, breast and uterus for women, prostate for
men) and lymphoma, gastrointestinal diseases (diverticulitis,
ulcers), infections (hepatitis), lung disease (chronic obstruct-
ive pulmonary disease (COPD), asthma) and psychiatric dis-
orders (depression).
3. Coexisting risk factors. Risk factors for cardiovascular dis-
eases (hypertension, diabetes, dyslipidaemia, family history
of myocardial infarction or sudden death), risk factors for
infectious diseases and vaccination status, risk factors for
cancers (family history of prostate, breast or colon cancer;
adenomatosus polyposis and/or personal history of inﬂam-
matory bowel disease (for colon cancer) and history of
numerous (>40) nevi for skin cancer).
4. Compliance with current national recommendations regard-
ing management (prevention, detection and treatment) of
these comorbidities. For example, annual estimation of car-
diovascular risk.
For each patient, information was gathered by a study investi-
gator during a face-to-face interview at a dedicated study visit
and through review of the medical record.
Data analysis
The ﬁrst step of the analysis was to describe the baseline charac-
teristics of the enrolled patients, by country, including the preva-
lence of each comorbidity and associated disease risk factors (%
and 95% CI).
To estimate any disparity that might exist between published
recommendations and daily clinical practice in the prevention,
detection and management of these comorbidities, the percentage
of patients monitored and managed according to national guide-
lines was calculated. The deﬁnition of ‘optimal’ management for
the evaluated comorbidities was primarily based on recommenda-
tions made by international scientiﬁc societies17 18 and/or national
healthcare systems25 and/or the recommendations of the French
Society of Rheumatology to prevent, detect and control comorbid-
ities in patients with inﬂammatory rheumatic diseases.26
For cardiovascular diseases, a patient was considered to be
optimally monitored when risk factors for cardiovascular events
(eg, blood pressure, blood glucose level, low-density lipoprotein
(LDL) cholesterol level) were evaluated annually. Patients older
than 50 years were considered to be managed optimally if they
were receiving an antithrombotic drug, in the setting of a past
thrombotic cardiovascular event, or if their Framingham Risk
Score27 was calculated to be 20% or more above the upper limit
of normal after being adjusted for RA (multiplied by a factor of
1.5), in the presence of speciﬁc RA characteristics.22 Finally, we
evaluated the proportion of patients in whom the systematic
evaluation of risk factors for cardiovascular diseases during the
conduct of the study detected hypertension (eg, systolic pressure
>140 mm Hg or diastolic pressure >80 mm Hg or
>130 mm Hg and 70 mm Hg, respectively, in the setting of
concomitant diabetes mellitus26), elevated LDL cholesterol
(above the targeted value deﬁned with regard to the number of
concomitant additional cardiovascular risk factors28) and hyper-
glycaemia (random blood glucose level >1.26 g/L28).
A patient was considered to be monitored optimally for infec-
tious diseases if he or she had had (1) a dental examination
within the previous year, (2) an inﬂuenza vaccination within the
previous year, and (3) a pneumococcal vaccination within the
previous 5 years.
A patient was considered to be monitored optimally for cancer
if age- and sex-appropriate cancer screening recommendations
for the general population were followed. A male patient without
known prostate cancer was considered to have been screened
optimally for prostate cancer if a digital rectal examination and
prostate-speciﬁc antigen (PSA) level had been performed
between the ages of 50 and 75 years (or between the ages of 45
and 75 years for patients of African ancestry) or with at least two
ﬁrst-degree relatives who had prostate cancer. Subsequently, this
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evaluation had to have been repeated every 3 years for those with
PSA <1 ng/mL and annually for those with PSA between 1 and
4 ng/mL. For men with PSA >4 ng/mL, evaluation by an urolo-
gist was required for the patient to be considered to have been
monitored optimally.28 For breast cancer detection, a woman
between the ages of 50 and 74 years without known breast
cancer was considered to have been screened optimally if a mam-
mogram had been performed within 2 years of the study visit.28
For uterine cancer detection, a woman between the ages of 25
and 65 years without known uterine cancer was considered to
have been monitored optimally if a Papanicolaou smear of the
cervix had been performed within 3 years of the study visit.28
For colon cancer screening, a patient over 50 years old without
known colon cancer was considered to have been optimally mon-
itored if stool had been tested for occult blood and at least one
colonoscopy had been performed. For those patients at high risk
of developing colon cancer (eg, those with inﬂammatory bowel
disease or with at least two ﬁrst-degree relatives who had colon
or rectal cancer or at least one ﬁrst-degree relative with adenoma-
tous polyposis or with Lynch syndrome), a colonoscopy had to
have been performed in the 2 years before the study visit for a
patient to be considered to have been optimally monitored.28 For
skin cancer detection, a patient was considered to be optimally
monitored if he or she had been examined at least once by a
dermatologist; if more than 40 nevi were present, annual evalu-
ation by a dermatologist was required for optimal monitoring.28
For lung cancer screening, a patient was considered to have been
monitored optimally if a chest radiograph had been performed
after the onset of RA.26
A patient was considered to have been screened optimally for
osteoporosis if at least one bone densitometry study had been
performed after the onset of RA and if he or she was taking
vitamin D supplementation at the time of the study visit.26
RESULTS
Patients and study course
A total of 4586 patients were recruited by investigators in the 17
participating countries between 2011 and 2012. Because a dispro-
portionately high number of subjects were enrolled in South
Korea (n=1052) compared with each of the other 16 countries,
400 patients from South Korea were randomly selected for inclu-
sion in the analysis. Fourteen patients from a single centre were
excluded from the current analysis because of too many missing
data, leaving a total of 3920 patients for further evaluation.
The baseline characteristics are summarised in table 1. There
was enormous intercountry variability for some characteristics:
patients in North Africa tended to have more active and more
severe disease, and fewer patients in some South American
countries had been treated with biological agents. Detailed com-
parisons of the baseline characteristics for each individual
country are provided in online supplementary tables S1 and S2.
Prevalence of comorbidities
The prevalence of those comorbidities that were evaluated is
depicted in ﬁgure 1. Depression (past or current symptoms) was
the most commonly observed comorbidity (mean 15.0%, 95%
CI 13.8% to 16.1%); however, the prevalence of depression
varied widely among countries (from 2% in Morocco to 33%
in the USA).
There was a history of ischaemic cardiovascular disease (myo-
cardial infarction or stroke) in 6.0% (95% CI 5.3% to 6.8%) of
the patients. This prevalence ranged from a low of 1% in
Morocco to a high of 17% in Hungary. A history of any solid
tumour, excluding basal cell skin cancers, was found in 4.5%
(95% CI 3.9% to 5.2%) of the patients and ranged from a low of
0.3% in Egypt to a high of 12.5% in the USA). Hepatitis B infec-
tion was observed more frequently in Italy (9%) and Taiwan
(7%) than in other countries (2.8% (95% CI 2.3% to 3.3%)).
The prevalence of hepatitis C infection was highest in Italy
(6.6%), Egypt (6.8%) and Taiwan (4.8%). The overall prevalence
of past or present gastrointestinal ulcer was 10.8% (95% CI
9.8% to 11.8%). This ranged from a low of 1% in Morocco to a
high of 22% in Egypt. Episodes of diverticulitis that had required
surgical intervention were rarely observed (0.4% (95% CI 0.2%
to 0.6%)). Pulmonary diseases, especially COPD, were observed
less commonly in Asian countries ( Japan, 1.4%; Korea, 1.3%;
Taiwan, 0.3%) than in European countries or the USA (Hungary,
8.0%; USA, 7.5%). Detailed listings by country of the prevalence
of the various comorbidities, grouped by category, are presented
in online supplementary tables S3–S7.
Table 1 Baseline patient and disease characteristics of the 3920 analysed patients enrolled in the COMORA Study
Variable
Results
Global results Extremes (countries)
Number 3920 From 30 (Uruguay) to 411 (France)
Female gender (%) 81.7 From 66 (Netherlands) to 91 (Venezuela)
Age (years), mean±SD 56±13 From 48 (Morocco/Egypt) to 63 ( Japan)
Smoking status (% current smokers) 13.2 From 0.9 (Morocco) to 48 (Austria)
Educational level (% university or graduate school) 24.5 From 5.3 (Italy) to 75 (Netherlands)
Marital status (% married) 69.7 From 50 (Venezuela) to 86 (Netherlands)
BMI (% overweight or obese) 50.7 From 0 (Netherlands) to 69 (USA)
Work status (% currently employed) 31.4 From 16 (Morocco) to 46 (USA)
Disease duration (years), mean±SD 9.6±8.7 From 7 (Morocco) to 14 (France)
DAS28–ESR, mean±SD 3.7±1.6 From 2.6 (Netherlands) to 5.3 ( Egypt)
HAQ, mean±SD 1.0±0.7 From 0.7 (Taiwan) to 1.5 (Morocco)
Prednisone (% currently taking) 54.3 From 9 (UK) to 82 (Morocco)
NSAID use (% having taken dose during previous 3 months) 55.2 From 25 (Morocco) to 94 (Taiwan)
MTX (% ever treated) 88.6 From 79 (Italy) to 98 (UK)
Any biological therapy (% ever treated) 38.9 From 3 (Uruguay) to 77 (UK)
BMI, body mass index; DAS28–ESR, Disease Activity Score using 28 joints–erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MTX, methotrexate; NSAID,
non-steroidal anti-inflammatory drug.
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Prevalence of risk factors for comorbidities
The prevalence of various risk factors for cardiovascular disease
and several malignancies is depicted in ﬁgure 2. As might be
expected, given the increased prevalence of cardiovascular
disease associated with RA, the most prevalent risk factors were
those that predispose to cardiovascular disease, such as
increased Framingham Risk Score (42.8% (95% CI 41.2% to
44.3%)), hypertension (40.4% (95% CI 38.9% to 41.9%)) and
hypercholesterolaemia (31.7% (95% CI 30.3% to 33.2%)). As
with the prevalence of comorbidities, there was considerable
intercountry variability in the prevalence of risk factors. For
example, the prevalence of smoking ranged from 3% in
Morocco to 48% in Austria. Detailed listings by country of the
prevalence of the various risk factors, grouped by comorbidity,
are presented in online supplementary tables S8 and S9.
Management of comorbidities
Cardiovascular diseases
Annual evaluation of cardiovascular risk, including measure-
ment of blood pressure, total serum cholesterol (high-density
lipoprotein (HDL) and LDL), blood glucose and serum creatin-
ine, was performed in 59.4% (95% CI 57.9% to 60.9%) of the
patients. Of the 236 patients who had a prior myocardial infarc-
tion or stroke, 162 (68.6%) were currently receiving an antith-
rombotic drug, but 74 (31.4%) were not. Among the other
3684 patients who had no history of myocardial infarction or
stroke, 366 would appropriately have been given prophylactic
antithrombotic drug treatment because they were older than
50 years and had a calculated Framingham Risk Score above
20%; however, of these, 299 were not receiving any antithrom-
botic agent. Thus, 373 (9.5%) of the total number of patients
Figure 1 Prevalence of evaluated
comorbidities in the 3920 patients
with rheumatoid arthritis. COPD,
chronic obstructive pulmonary disease.
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enrolled in this study should have been treated with antithrom-
botic drug prophylaxis, but were not being managed optimally
to prevent cardiovascular events (ﬁgure 3).
The systematic assessment of certain cardiovascular risk
factors in this study allowed their detection in previously
undiagnosed patients. Among the 2489 patients without known
hypertension, elevated blood pressure was detected in 454
(18%). An elevated blood glucose level was detected in 131
(3.7%) of the 3522 patients without previously diagnosed dia-
betes mellitus. An LDL cholesterol level above the optimal
target was detected in 325 (11.0%) of the 2966 patients not
previously diagnosed to have a dyslipidaemia or not receiving
lipid-lowering therapy.
Infectious diseases
During the year before the study visit, 42.3% (95% CI 40.8%
to 43.9%) of all 3920 enrolled patients had undergone a dental
examination. However, fewer patients were vaccinated in
accordance with current recommendations: an inﬂuenza vaccin-
ation had been performed during the year before the study visit
in only 938 (25.3% (95% CI 23.9% to 26.7%)) of the patients
and a pneumococcal vaccination had been performed within
5 years of the study visit in only 636 (17.2% (95% CI 16.0% to
18.4%)) of the patients. Both an inﬂuenza and a pneumococcal
vaccination were performed according to current recommenda-
tions in only 316 (10.3% (95% CI 9.3% to 11.4%)) of the
patients.
Cancers
Optimal screening for malignancies, according to recommended
guidelines, was performed in only 909 (23.9%) of the patients
for skin cancers, 608 (26.7%) of the patients for colon cancer,
202 (38.2%) of the patients for prostate cancer, 938 (51.5%) of
the patients for breast cancer, and 1383 (59.3%) of the patients
for uterine cancer.
Osteoporosis
Bone densitometry had been performed at least once in 2281
(58.2% (95% CI 56.6% to 59.7%)) of the 3920 patients. Of all
enrolled patients, 1733 (44.4% (95% CI 42.9% to 46.0%))
were receiving vitamin D supplementation at the time of the
study visit.
Detailed listings by country of the percentage of patients opti-
mally monitored for cardiovascular, infectious and cancer dis-
eases are presented in online supplementary tables S10–S12.
DISCUSSION
This is the ﬁrst population-based, cross-sectional observational
study to assess multiple comorbidities and their management
among a relatively large sample of patients with RA who were
enrolled by rheumatologists in 17 participating countries on ﬁve
different continents. This study conﬁrms not only the relatively
high prevalence of comorbidities among patients with RA, but
also considerable intercountry variability in the prevalence of
these comorbidities.29 It demonstrates that, at present, the man-
agement of comorbidities in patients with RA is far from
optimal. As in this study, the systematic evaluation of RA
patients for evidence of comorbidities may uncover previously
undiagnosed conditions in some patients.
An important aim of this study was to evaluate the gap
between current recommendations for detecting, managing and
preventing comorbidities and their implementation in observed
daily practice. To accomplish this objective, the scientiﬁc commit-
tee for the study created an a priori deﬁnition of optimal moni-
toring based largely on current recommendations provided by
various international medical organisations. The optimal LDL
cholesterol level on which the analysis of this study was based is
that currently recommended by the French Ministry of Health,28
and this standard was applied to all study subjects in all partici-
pating countries regardless of local recommendations. However,
for comorbidities such as cardiovascular disease, deﬁnitions were
country-speciﬁc, and recommendations for monitoring or pre-
vention varied slightly between participating countries. For
example, the indication for initiation of antithrombotic drug
prophylaxis was a history of a prior cardiovascular event in some
countries and a >20% risk of experiencing a cardiovascular
event based on the Framingham Risk Score in others.27 Had this
study used other standards for the detection, management and
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prevention of comorbidities,30 31 it might have found slightly dif-
ferent proportions. Regardless, this study demonstrates that com-
pliance with recommended strategies is far from perfect and that
this varies signiﬁcantly among countries.
Although this study has numerous strengths, it also has
several weaknesses. The comorbidities evaluated were selected
for the study by the scientiﬁc committee and were not
all-inclusive; some important comorbidities, such as tubercu-
losis, were not among those assessed. Despite the principal
investigators in each country having been instructed to recruit
rheumatologists working in different practice settings to enrol
RA patients, it cannot be guaranteed that the prevalent cohort
of 3920 patients studied here were fully representative of all
RA patients in the participating countries. The study did not
enrol RA patients from general practices who were not under
the care of a rheumatologist. Moreover, some of the intercoun-
try variability in the degree of RA disease activity observed in
this study might reﬂect differences in the reason for which the
patient was visiting the rheumatologist at the time of study par-
ticipation: in some countries, patients are evaluated routinely
even when their RA is under good control, whereas, in other
countries, patients go to see their rheumatologist only when
they experience a ﬂare of disease activity. Also, cultural differ-
ences among patients recruited from different countries might
lead to diverse interpretations of questions included in the
questionnaire. Varied interpretation of the term ‘depression’ by
subjects in different countries could account, in part, for the
wide differences observed across countries in the prevalence of
depression.
Several different types of bias are inherent in a prevalent
cohort study of a chronic disease. The prevalence of some
comorbidities might be overestimated because of diagnostic bias,
in that patients with RA may more likely be offered screening
for recognised comorbidities, or because of reporting bias, in
that RA patients may more likely be diagnosed with comorbid-
ities known to be associated with this inﬂammatory disease. The
prevalence of other comorbidities might be underestimated
because of truncation bias, in that RA patients with potentially
life-threatening comorbidities may have been lost from the
population before the cohort was enrolled. These biases may
produce diverse effects in different countries. The lack of a
comparator group without RA did not allow comparison in this
study between the observed prevalence of comorbidities and
their optimal management among RA patients with that in the
general population or among patients with another disease state.
This study achieved its main objective, which was to evaluate
and demonstrate intercountry variation in the detection, manage-
ment and prevention of comorbidities among RA patients. It
shows clear differences in the prevalence of certain risk factors,
which might inﬂuence national policies regarding prevention strat-
egies. For example, the high prevalence of tobacco smoking found
among RA patients in the Netherlands (41.2%) and Austria
(47.5%) might prompt targeted programmes to reduce this behav-
iour, which clearly predisposes not only to the development of
RA,32 but also to cardiovascular disease33 and lung cancer,34 both
of which are also signiﬁcant comorbidities of RA. Other studies
that have compared the prevalence of comorbidities among RA
patients with those in the general population have shown a higher
prevalence of cardiovascular events,8 infections,10 11 osteoporotic
fractures12 and lung cancer14 among RA patients. Nevertheless,
the relatively large sample of RA patients who were enrolled from
17 countries on various continents allowed the present study to
conﬁrm the high prevalence of hepatitis in Asian35 36 and southern
European countries37 and in Egypt.38 39
This study conﬁrms the observation that monitoring of RA
patients for cardiovascular risk is suboptimal19 40–42 and extends
this assumption to other comorbidities. Moreover, it demon-
strates that systematic assessment of RA patients for comorbidities
facilitates the detection of abnormalities such as elevated blood
pressure, hyperglycaemia and hypercholesterolaemia. These ﬁnd-
ings are in agreement with those of previous studies that sug-
gested that cardiovascular risk factors are not optimally
monitored and managed in 30–50% of RA patients.40 41
Given the ﬁndings of the present study, the question arises as to
how best to improve this situation. The treating rheumatologist
should consider the periodic assessment of comorbidities as one of
the tasks involved in treating a patient with RA. This should be
carried out in collaboration with primary care providers and other
specialists who are involved in the care of these patients. However,
the increasing complexity of managing treatment of RA with
effective combinations of traditional and biological DMARDs in
the setting of progressively decreasing amounts of time available
for direct interaction with the patient makes this additional
responsibility challenging. The development and implementation
of standardised programmes to detect, manage and prevent
comorbidities in daily clinical practice, working in partnership
with other healthcare providers such as nurses,42 43 might greatly
facilitate the identiﬁcation of and intervention to reduce the preva-
lence of comorbidities among patients with RA.
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